Can a single injection of huperzine a unlock new treatments?

NCT ID NCT06570655

NEW Completed Knowledge-focused Sponsor: Wanbangde Pharmaceutical Group Co., LTD Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This early-stage trial is testing how a single injection of huperzine A moves through the body and affects a key enzyme in red blood cells. Twelve healthy Chinese volunteers will receive the drug in four different ways to measure its concentration over time and its effect on acetylcholinesterase activity. The goal is to understand the drug's behavior and dosing, which could inform future studies for conditions like Alzheimer's disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Huperzine A injection
What this could lead to: If successful, this could help determine the right dosing for huperzine A, potentially supporting its development as a treatment for conditions like Alzheimer's disease.
What could go wrong: This is an early-phase study in a small group of healthy volunteers, so results may not predict effects in patients. The drug may also cause side effects, and the study is not designed to test effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SUBJECTS

Contacts and locations

Locations

Clinical trial institution of the Zhejiang Xiaoshan hospital

Hangzhou, China/Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.